AOD-9604 vs Vilon
Side-by-side comparison of key properties, dosing, and research.
- Summary
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
- Half-Life
- 30-45 minutes injectable; longer with nasal spray formulation
- Very short as a free dipeptide; effects mediated via gene regulation
- Admin Route
- SubQ, Intranasal, Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 300-600 mcg
- 1–2 mg SC daily or 5–10 mg oral daily
- Frequency
- Once daily
- Once daily
- Key Benefits
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Immune system modulation and restoration
- Lifespan extension (30–40% in animal studies)
- T-cell and NK-cell activation
- Epigenetic anti-aging activity
- Reduces oxidative stress markers
- Antioxidant gene upregulation
- May prevent age-related immune senescence
- Anti-tumor immune surveillance
- Side Effects
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Excellent safety profile, decades of Russian clinical use
- Rare: mild injection site reaction
- Very rare: mild allergic reaction
- Stacks With
- —
- —